eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | neurofibromatosis 2 |
| Comorbidity | C0027859|vestibular schwannoma |
| Sentences | 18 |
| PubMedID- 22844108 | This single-institution phase ii study was performed to estimate the response rate to lapatinib in neurofibromatosis type 2 (nf2) patients with progressive vestibular schwannoma (vs). |
| PubMedID- 24718755 | Audiovestibular characteristics of small cochleovestibular schwannomas in neurofibromatosis type 2. |
| PubMedID- 24436903 | Six patients had neurofibromatosis type 2 (nf2) with bilateral vestibular schwannomas and meningiomas, and the four others had aggressive recurrent meningiomas. |
| PubMedID- 22681725 | Additionally, this method of drug delivery may have important implications in the treatment of patients with vestibular schwannomas associated with neurofibromatosis type 2. |
| PubMedID- 24311643 | Methods: we conducted a single-institution, prospective, 2-stage, open-label phase ii study to estimate the response rate to everolimus in neurofibromatosis type 2 (nf2) patients with progressive vestibular schwannoma (vs). |
| PubMedID- 25567352 | Phase ii study of mtorc1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. |
| PubMedID- 20150363 | Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 20736812 | We sought to determine the activity of erlotinib for progressive vestibular schwannoma (vs) associated with neurofibromatosis 2 (nf2). |
| PubMedID- 22483820 | The focus is on management of sporadic, unilateral vestibular schwannomas, because patients with neurofibromatosis type 2 pose different management problems best discussed separately. |
| PubMedID- 22805104 | Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. |
| PubMedID- 21817944 | Management strategy of vestibular schwannoma in neurofibromatosis type 2. |
| PubMedID- 26287269 | Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2. |
| PubMedID- 26377980 | Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 20848106 | Furthermore, tumour location and patient age may point to a familial tumour syndrome as in the case of neurofibromatosis type 2 (nf2) with typical bilateral vestibular schwannoma in young age. |
| PubMedID- 24335931 | Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2. |
| PubMedID- 24393766 | Two phase ii clinical trials (nct01207687, nct01125046) are assessing the effectiveness of bevacizumab in treating neurofibromatosis 2 patients with symptomatic vestibular schwannomas and recurrent or progressive meningiomas. |
| PubMedID- 26108240 | Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage. |
| PubMedID- 24349188 | Five patients after bvds for bilateral vestibular schwannomas due to neurofibromatosis type ii (4 females and 1 male, age range = 39–60 years, m = 46.4 years, sd = 8.2), who did not have any functioning ear were tested with monocular dual-search coils in ludwig-maximilians university [18]. |
Page: 1